1990年与2017年中国前列腺癌疾病负担分析  

Analysis of the burden of prostate cancer in China in 1990 and 2017

作　　者：邓通 蔡林[3,4] 陈征 郭佳[6] 黄兴 柯昌兴[10] 李文智[11] 李江[12,13,14] 卢冠军 刘霄强[16] 范晋海 曾宪涛[1,7] Tong DENG;Lin CAI;Zheng CHEN;Jia GUO;Xing HUANG;Chang-Xing KE;Wen-Zhi LI;Li JIANG;Guan-Jun LU;Xiao-Qiang LIU;Jin-Hai FAN;Xian-Tao ZENG(Center for Evidence-Based and Translational Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Institutes of Evidence-Based Medicine and Knowledge Translation,Henan University,Kaifeng 475000,Henan Province,China;Department of Urology,Peking University First Hospital,Beijing 100034,China;Institute of Urology,Peking University,Beijing 100034,China;Department of Urologic Sciences,University of British Columbia,British Columbia V5Z 1M9,Canada;Department of Urology,People's Hospital of Wuhan University,Wuhan 430060,China;Department of Urology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Institute of Urology,Wuhan University,Wuhan 430071,China;Hubei Provincial Engineering Research Center for Precision Diagnosis and Therapy Technology and Translational Medicine,Wuhan 430071,China;Department of Urology,Second Affiliated Hospital of Kunming Medical University,Kunming 650000,China;Department of Urology,Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200011,China;National Cancer Center,Beijing 100021,China;National Cancer Clinical Medical Research Center,Beijing 100021,China;Cancer Early Diagnosis and Early Treatment Office,Cancer Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100021,China;Department of Urology,The General Hospital of Ningxia Medical University,Yinchuan 750004,China;Department of Urology,the First Affiliated Hospital of Nanchang University,Nanchang 330000,China;Department of Urology,First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710000,China;Institute of Urology,Xi'an Jiaotong University,Xi'an 710000,China)

机构地区：[1]武汉大学中南医院循证与转化医学中心,武汉430071 [2]河南大学循证医学与临床转化研究院,河南开封475000 [3]北京大学第一医院泌尿外科,北京100034 [4]北京大学泌尿外科研究所,北京100034 [5]英属哥伦比亚大学泌尿学系,加拿大不列颠哥伦比亚省V5Z 1M9 [6]武汉大学人民医院泌尿外科,武汉430060 [7]武汉大学中南医院泌尿外科,武汉430071 [8]武汉大学泌尿外科研究所,武汉430071 [9]肿瘤精准诊疗技术与转化医学湖北省工程研究中心,武汉430071 [10]昆明医科大学第二附属医院泌尿外科,昆明650000 [11]上海交通大学医学院附属第九人民医院泌尿外科,上海200011 [12]国家癌症中心,北京100021 [13]国家肿瘤临床医学研究中心,北京100021 [14]中国医学科学院北京协和医学院肿瘤医院癌症早诊早治办公室,北京100021 [15]宁夏医科大学总医院泌尿外科,银川750004 [16]南昌大学第一附属医院泌尿外科,南昌330000 [17]西安交通大学第一附属医院泌尿外科,西安710000 [18]西安交通大学泌尿外科研究所,西安710000

出　　处：《医学新知》2020年第4期252-259,共8页New Medicine

基　　金：国家自然科学基金面上项目(81972408);上海市科委生物医药领域重点项目(18441901700)。

摘　　要：目的分析1990年与2017年中国前列腺癌的疾病负担及变化趋势。方法采用2017年全球疾病负担(The Global Burden of Diseases 2017,GBD 2017)的研究结果,通过前列腺癌发病率、死亡率、伤残调整寿命年(Disability-Adjusted Life Years,DALY)、过早死亡损失寿命年(Years of Life Lost,YLL)、伤残损失寿命年(Years Lived with Disability,YLD)及其标化率对1990年和2017年间中国前列腺癌的疾病负担进行描述。结果2017年中国前列腺癌发病例数为14.49万,标化发病率为16.57/10万,死亡例数为5.17万,标化死亡率为6.8/10万。与1990年相比,发病例数增加了432.72%,标化发病率增加了98.21%,死亡例数增加了158.5%,标化死亡率降低了3.82%。发病率和死亡率随年龄的增加呈现出上升的趋势。相比1990年,2017年我国前列腺癌的DALY标化率降低了3.81%,YLL标化率降低了9.73%,YLD标化率增加了134.56%。结论与1990年相比,2017年我国前列腺癌的疾病负担整体呈下降趋势,但YLD呈现上升的趋势。老年人群的前列腺癌疾病负担仍然很高,应为重点关注人群。Objective To analyze the trend of incidence,mortality and disease burden of prostate cancer in China between 1990 and 2017.Methods Based on the results of the Global Burden of Diseases 2017(GBD 2017),Incidence,Mortality,Disability-Adjusted Life Years(DALY),Years of Life Lost(YLL),and Years Lived with Disability(YLD)of prostate cancer and its standardized rate were used to describe the burden of prostate cancer in China between 1990 and 2017.Results In 2017,the number of cases of prostate cancer in China was 144,900,the standardized incidence was 16.57/100000,the number of deaths was 51,700,and the standardized mortality was 6.8/100000.Compared with 1990,the number of cases increased by 432.72%,the standardized incidence increased by 98.21%,the number of deaths increased by 158.5%,and the standardized mortality decreased by 3.82%.Incidence and mortality are increasing with age.Compared with 1990,in 2017,the DALY standardization rate of prostate cancer in China decreased by 3.81%,the YLL standardization rate decreased by 9.73%,and the YLD standardization rate increased by 134.56%.Conclusions Compared with 1990,the overall disease burden of prostate cancer in China in 2017 showed a downward trend,but YLD showed an upward trend.The burden of prostate cancer disease in the elderly is still high and should be the focus of attention.

关 键 词：前列腺癌 发病率 死亡率 疾病负担 伤残调整寿命年 

分 类 号：R737.25[医药卫生—肿瘤]